1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697. [
DOI:10.1016/S0140-6736(07)61345-2]
2. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 91: 4842-4848. [
DOI:10.1210/jc.2006-1327]
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. [
DOI:10.1210/jc.2006-0178]
4. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77-83. [
DOI:10.1093/molehr/gah015]
5. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88: 5957-5962. [
DOI:10.1210/jc.2003-030727]
6. Wild RA, Carmina E, Diamanti-Kandarakis E. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Exess and polycystic ovary syndrome Society. J Clin Endocrinol Metab 2010; 95: 2038. [
DOI:10.1210/jc.2009-2724]
7. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012; 27: 2494-2502. [
DOI:10.1093/humrep/des213]
8. Villarroel C, MerinoPM, Lo´pez P, Eyzaguirre FC. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011; 26: 2861-2868. [
DOI:10.1093/humrep/der223]
9. Chao KC, Ho CH, Shyong WY, Huang CY, Tsai SC, Cheng HY, et al. Anti mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J Chin Med Assoc 2012; 75: 70-74. [
DOI:10.1016/j.jcma.2011.12.007]
10. Carmina E, Campagna AM, Mansuet P, Vitale G, Kort D, Lobo R. Dose the level of serum anti mullerian hormone predict ovulatory function in women with PCOS with aging. Fertil Steril 2012; 98: 1043-1046. [
DOI:10.1016/j.fertnstert.2012.06.017]
11. Woo HY, Kim KH, Rhee EJ. Differeces of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocrine J 2012; 59: 781-790. [
DOI:10.1507/endocrj.EJ12-0055]
12. Pingy P, Jonard S, Robert Y, Dewailly D. Serum anti- Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 941-944. [
DOI:10.1210/jc.2005-2076]
13. Swellam M, Khaial A, Mosa T, El-Baz H. Anti-Mullerian and androgens hormones in women66 with polycystic ovary syndrome undergoing IVF/ICSI. Iran J Reprod Med 2013; 11: 883-890.